TY - JOUR
T1 - Treatments used for obsessive-compulsive disorder-An international perspective
AU - Brakoulias, Vlasios
AU - Starcevic, Vladan
AU - Albert, Umberto
AU - Arumugham, Shyam Sundar
AU - Bailey, Brenda E
AU - Belloch, Amparo
AU - Borda, Tania
AU - Dell'Osso, Liliana
AU - Elias, Jason A
AU - Falkenstein, Martha J
AU - Ferrao, Ygor A
AU - Fontenelle, Leonardo F
AU - Jelinek, Lena
AU - Kalogeraki, Leto
AU - Kay, Brian
AU - Laurito, Luana D
AU - Lochner, Christine
AU - Maina, Giuseppe
AU - Marazziti, Donatella
AU - Martin, Andrew
AU - Matsunaga, Hisato
AU - Miguel, Euripedes C
AU - Morgado, Pedro
AU - Mourikis, Irakis
AU - Pasquini, Massimo
AU - Perez Rivera, Rodrigo
AU - Potluri, Sriramya
AU - Reddy, Janardhan Y C
AU - Riemann, Brian C
AU - do Rosario, Maria Conceição
AU - Shavitt, Roseli G
AU - Stein, Dan J
AU - Viswasam, Kirupumani
AU - Wang, Zhen
AU - Fineberg, Naomi A
N1 - © 2019 John Wiley & Sons, Ltd.
PY - 2019/1/10
Y1 - 2019/1/10
N2 - OBJECTIVE: The objective of this study was to characterise international trends in the use of psychotropic medication, psychological therapies, and novel therapies used to treat obsessive-compulsive disorder (OCD).METHODS: Researchers in the field of OCD were invited to contribute summary statistics on the characteristics of their samples. Consistency of summary statistics across countries was evaluated.RESULTS: The study surveyed 19 expert centres from 15 countries (Argentina, Australia, Brazil, China, Germany, Greece, India, Italy, Japan, Mexico, Portugal, South Africa, Spain, the United Kingdom, and the United States) providing a total sample of 7,340 participants. Fluoxetine (n = 972; 13.2%) and fluvoxamine (n = 913; 12.4%) were the most commonly used selective serotonin reuptake inhibitor medications. Risperidone (n = 428; 7.3%) and aripiprazole (n = 415; 7.1%) were the most commonly used antipsychotic agents. Neurostimulation techniques such as transcranial magnetic stimulation, deep brain stimulation, gamma knife surgery, and psychosurgery were used in less than 1% of the sample. There was significant variation in the use and accessibility of exposure and response prevention for OCD.CONCLUSIONS: The variation between countries in treatments used for OCD needs further evaluation. Exposure and response prevention is not used as frequently as guidelines suggest and appears difficult to access in most countries. Updated treatment guidelines are recommended.
AB - OBJECTIVE: The objective of this study was to characterise international trends in the use of psychotropic medication, psychological therapies, and novel therapies used to treat obsessive-compulsive disorder (OCD).METHODS: Researchers in the field of OCD were invited to contribute summary statistics on the characteristics of their samples. Consistency of summary statistics across countries was evaluated.RESULTS: The study surveyed 19 expert centres from 15 countries (Argentina, Australia, Brazil, China, Germany, Greece, India, Italy, Japan, Mexico, Portugal, South Africa, Spain, the United Kingdom, and the United States) providing a total sample of 7,340 participants. Fluoxetine (n = 972; 13.2%) and fluvoxamine (n = 913; 12.4%) were the most commonly used selective serotonin reuptake inhibitor medications. Risperidone (n = 428; 7.3%) and aripiprazole (n = 415; 7.1%) were the most commonly used antipsychotic agents. Neurostimulation techniques such as transcranial magnetic stimulation, deep brain stimulation, gamma knife surgery, and psychosurgery were used in less than 1% of the sample. There was significant variation in the use and accessibility of exposure and response prevention for OCD.CONCLUSIONS: The variation between countries in treatments used for OCD needs further evaluation. Exposure and response prevention is not used as frequently as guidelines suggest and appears difficult to access in most countries. Updated treatment guidelines are recommended.
KW - antipsychotics
KW - benzodiazepines
KW - cross-cultural study
KW - obsessive–compulsive disorder
KW - pharmacotherapy
KW - selective serotonin reuptake inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85059870802&partnerID=8YFLogxK
U2 - 10.1002/hup.2686
DO - 10.1002/hup.2686
M3 - Article
C2 - 30628745
SN - 0885-6222
VL - 34
SP - e2686
JO - Human Psychopharmacology: Clinical and Experimental
JF - Human Psychopharmacology: Clinical and Experimental
IS - 1
M1 - e2686
ER -